NeuBase Therapeutics to Present at Upcoming Investor Conferences in December
Evercore ISI HealthCONx Conference panel discussion at 12:30 p.m. ET on December 3rd
Piper Jaffray 31st Annual Healthcare Conference presentation at 8:30 a.m. ET on December 4th
PITTSBURGH, Nov. 25, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will participate in a panel discussion at the Evercore ISI HealthCONx Conference 2019, as well as present a corporate overview and business update at the 31st Annual Piper Jaffray Healthcare Conference, which are both being held in December.
|
Conferences Details: | |
| Event: | Evercore ISI HealthCONx Conference 2019 |
| Panel: | GenomeRx Therapeutics: The Next Exciting Wave |
| Date: | Tuesday, Dec. 3, 2019 |
| Time: | 12:30 p.m. EST |
| Location: | Four Seasons Hotel, Boston |
| Event: | 31st Annual Piper Jaffray Healthcare Conference |
| Date: | Wednesday, Dec. 4, 2019 |
| Time: | 8:30 a.m. EST |
| Location: | Lotte New York Palace, New York |
About NeuBase Therapeutics
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.
NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576
NeuBase Media Contact:
Travis Kruse
Russo Partners
travis.kruse@russopartnersllc.com
OP: (212) 845-4272
Ned Berkowitz
Russo Partners
ned.berkowitz@russopartnersllc.com
OP: (646) 942-5629
Released November 25, 2019